

Relative Tumor Volume ± SEM
Time (Day)
Vehicle
TSL-1502 25 mg/kg
TSL-1502 50 mg/kg
AZD2281 25 mg/kg
AZD2281 50 mg/kg
Carboplatin 60 mg/kg
TSL-1502 25 mg/kg+Carboplatin 60 mg/kg
AZD2281 25 mg/kg+Carboplatin 60 mg/kg
0
2
4
6
8
0
2
6
9
13
16
21
27
34
37

FIG. 1




Average Weight ±SD (g)
Time (Day)
Vehicle
TSL-1502 25 mg/kg
TSL-1502 50 mg/kg
AZD2281 25 mg/kg
AZD2281 50 mg/kg
Carboplatin 60 mg/kg
TSL-1502 25 mg/kg+Carboplatin 60 mg/kg
AZD2281 25 mg/kg+Carboplatin 60 mg/kg
6
8
10
12
14
16
18
20
22
24
26
28
0
2
6
9
13
16
21
27
34
37

FIG. 2


The therapeutical effect of TSL-1502,AZD2281 alone or in combination with carboplatin on human breast cancer MX-1 nude mice subcutaneous xenografts
Vehicle
Vehicle
AZD2281 25mg/kg
AZD2281 50mg/kg
TSL-1502 25 mg/kg
TSL-1502 50 mg/kg



The therapeutical effect of TSL-1502,AZD2281 alone or in combination with carboplatin on human breast cancer MX-1 nude mice subcutaneous xenografts
Carboplatin 60mg/kg
TSL-1502+Carboplatin 25mg/kg, 60mg/kg
AZD2281+Carboplatin 25mg/kg, 60mg/kg

FIG. 3



Relative Tumor Volume ± SEM
Time (Day)
Vehicle
AZD2281 30 mg/kg+ Campto® 10 mg/kg
AZD2281 30 mg/kg
Campto® 10 mg/kg
TSL-1502 5 mg/kg+ Campto® 10 mg/kg
TSL-1502 15 mg/kg+ Campto® 10 mg/kg
TSL-1502 50 mg/kg+ Campto® 10 mg/kg
TSL-1502 50 mg/kg
0
2
4
6
8
10
12
14
0
7
10
14
17

FIG. 4



Average Weight (g)
24
22
20
18
16
14
12
10
8
6
0
7
10
14
17
Time (Day)
Vehicle
AZD2281 30 mg/kg+ Campto® 10 mg/kg
AZD2281 30 mg/kg
Campto® 10 mg/kg
TSL-1502 5 mg/kg+ Campto® 10 mg/kg
TSL-1502 15 mg/kg+ Campto® 10 mg/kg
TSL-1502 50 mg/kg+ Campto® 10 mg/kg
TSL-1502 50 mg/kg

FIG. 5



The enhancement effect of TSL-1502, AZD2281 on CAMPTO® treated human colorectal cancer SW 620 nude mice subcutaneous xenografts
Vehicle
Vehicle
TSL-1502+CAMPTO®
5 mg/kg, 10mg/kg
TSL-1502+CAMPTO®
15 mg/kg, 10mg/kg
TSL-1502+CAMPTO®
50 mg/kg, 10mg/kg
TSL-1502
50mg/kg
AZD2281+CAMPTO®
30 mg/kg, 10mg/kg
AZD2281
30 mg/kg
CAMPTO®
10mg/kg

FIG. 6



Tumor Volumn(mm3)
Control
DDP(6mg/kg)
Veliparib(25mg/kg )+DDP(6mg/kg)
HD-199(6.25mg/kg )+DDP(6mg/kg)
HD-199(12.5mg/kg )+DDP(6mg/kg)
HD-199(25mg/kg )+DDP(6mg/kg)
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
-1000
d14 d16 d18 d20 d22 d24 d26 d28 d30 d32 d34 d36 d38 d40 d42 d44 d46 d48 d50
HD-199 po Bid d14-22
DDP sc qd d16.19
Days post implantation

FIG. 7



vehicle
DDP(6mg/kg)
veliparib(25mg/kg )+DDP
HD-199(6.25mg/kg )+DDP
HD-199(12.5mg/kg )+DDP
HD-199(25mg/kg )+DDP
Relative Volume of Tumor (RTV)
7000
6000
5000
4000
3000
2000
1000
0
d14 d16 d18 d20 d22 d24 d26 d28 d30 d32 d34 d36 d38 d40 d42 d44 d46 d48 d50
HD-199 po Bid d14-22
DDP sc qd d16.19
Days Post Implantation

FIG. 8



Body Weight(g)
30.00
25.00
20.00
15.00
10.00
5.00
0.00
Control
DDP(6mg/kg)
Veliparib(25mg/kg )+DDP(6mg/kg)
HD-199(6.25mg/kg )+DDP(6mg/kg)
HD-199(12.5mg/kg )+DDP(6mg/kg)
HD-199(25mg/kg )+DDP(6mg/kg)
d14
d16
d18
d20
d22
d24
d26
d28
d30
d32
d34
d36
d38
d40
d42
d44
d46
d48
d50
Days Post implantation

FIG. 9



TV(mm3)
18000.00
16000.00
14000.00
12000.00
10000.00
8000.00
6000.00
4000.00
2000.00
0.00
(2000.00)
vehicle
TMZ(50mg/kg)
Veliparib(25mg/kg ) +TMZ
HD-199(10mg/kg) +TMZ
HD-199(15mg/kg) +TMZ
HD-199(30mg/kg) +TMZ
d11
d13
d15
d17
d19
d21
d23
d25
d27
d29
d31
d33
Days post implantation

FIG. 10



RTV
6000.00
5000.00
4000.00
3000.00
2000.00
1000.00
0.00
vehicle
TMZ(50mg/kg)
Veliparib(25mg/kg) +TMZ
HD-199(10mg/kg) +TMZ
HD-199(15mg/kg) +TMZ
HD-199(30mg/kg) +TMZ
d11
d13
d15
d17
d19
d21
d23
d25
d27
d29
d31
d33
Days post implantation

FIG. 11



120
100
80
60
40
20
0
T/C(%)
TMZ(50mg/kg)
Veliparib(25mg/kg) +TMZ
HD-199(10mg/kg) +TMZ
HD-199(15mg/kg) +TMZ
HD-199(30mg/kg) +TMZ
d11
d13
d15
d17
d19
d21
d23
d25
d27
d29
d31
d33
Days post implantation

FIG. 12